Weight loss drugs effectively regulate impulse control - and the effects go far beyond snack food. Our economy is built on impulse purchases. The secondary effects of GLP-1 drugs will cause what has been called a “$100 trillion dollar disruption.” I’m not talking about societal changes deep in the future. Much of this is on a five-year timeline. You’ve heard of Ozempic and Wegovy, the brand names used by Novo Nordisk since FDA approval in 2021. Eli Lilly joined the market in late 2023 with Zepbound. Brand names will come and go; the generic term is GLP-1 drugs. A significant portion of the...